- Home
- VGAS vs ATRA Comparison
VGAS vs ATRA Comparison
Compare VGAS & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VGAS | ATRA |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3M | 38.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | VGAS | ATRA |
|---|---|---|
| Price | $1.75 | $4.79 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 17.9K | ★ 58.9K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $3.92 |
| 52 Week High | $3.92 | $19.15 |
Technical Indicators
Market Signals| Indicator | VGAS | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 45.70 |
| Support Level | $1.52 | $4.70 |
| Resistance Level | $2.06 | $5.47 |
| Average True Range (ATR) | 0.17 | 0.31 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 33.33 | 26.29 |
Price Performance
Historical ComparisonAbout VGAS Verde Clean Fuels Inc.
Verde Clean Fuels Inc is a renewable energy company specializing in the conversion of synthesis gas, or syngas, derived from diverse feedstocks, such as biomass, MSW, and mixed plastics, as well as natural gas (including synthetic natural gas) and other feedstocks, into liquid hydrocarbons that can be used as gasoline through a proprietary liquid fuels technology, the STG process.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).